New Delhi, July 23 -- Eli Lilly & Co.'s highly anticipated next-generation weight-loss shot didn't increase overall heart risk in a new study, the company said, helping dispel lingering concerns over its potential as it nears regulatory review.

Lilly's trial evaluated retatrutide's cardiovascular safety in people with obesity and heart disease after earlier studies raised questions about a possible increase in heart rhythm abnormalities. The latest findings - plus another new study in patients with obesity and diabetes - help solidify the drug's blockbuster potential.

However, Lilly will seek approval from US regulators later than investors hoped. The company said Thursday that it plans to file for US Food and Drug Administration approv...